123 related articles for article (PubMed ID: 3466668)
1. Late appearing 5q--marker in refractory anemia.
Heim S; Billström R; Kristoffersson U; Mandahl N; Mitelman F
Cancer Genet Cytogenet; 1987 Jan; 24(1):159-62. PubMed ID: 3466668
[TBL] [Abstract][Full Text] [Related]
2. 5q- syndrome in a child.
Uyttebroeck A; Brock P; De Groote B; Renard M; Dal Cin P; Van den Berghe H; Casteels-Van Daele M
Cancer Genet Cytogenet; 1995 Apr; 80(2):121-3. PubMed ID: 7736428
[TBL] [Abstract][Full Text] [Related]
3. Leukemic transformation in patients with 5Q- and additional abnormalities.
Larripa I; Acevedo S; Palau Nagore MV; Bengiò R; Mondini N; Slavutsky I
Haematologica; 1991; 76(5):363-7. PubMed ID: 1806438
[TBL] [Abstract][Full Text] [Related]
4. Refractory anemia with monosomy 2 and a double minute chromosome.
Prieto F; Badía L; Gomis F; Dieguez L
Cancer Genet Cytogenet; 1987 Oct; 28(2):367-71. PubMed ID: 3476193
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia.
Westbrook CA; Hsu WT; Chyna B; Litvak D; Raza A; Horrigan SK
Br J Haematol; 2000 Sep; 110(4):847-55. PubMed ID: 11054067
[TBL] [Abstract][Full Text] [Related]
6. High resolution analysis of the 5q-marker chromosome in refractory anemia.
Mitelman F; Manolova Y; Manolov G; Billström R; Heim S; Kristoffersson U; Mandahl N
Hereditas; 1986; 105(1):49-54. PubMed ID: 3793519
[No Abstract] [Full Text] [Related]
7. [Refractory anemia with 5q--anomaly. Clinical picture and follow-up of seven patients].
May D; Becher R
Med Klin (Munich); 1992 Aug; 87(8):408-11. PubMed ID: 1406472
[TBL] [Abstract][Full Text] [Related]
8. Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes.
Stewart B; Verdugo M; Guthrie KA; Appelbaum F; Deeg HJ
Br J Haematol; 2003 Dec; 123(5):879-85. PubMed ID: 14632779
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
[TBL] [Abstract][Full Text] [Related]
10. Deletion of the long arm of chromosome 5 (5q-) as a secondary event in the course of refractory anemia.
Baer MR; Dessypris EN
Cancer Genet Cytogenet; 1986 Jun; 22(2):169-76. PubMed ID: 3708550
[TBL] [Abstract][Full Text] [Related]
11. Unusual findings in two patients with acquired deletions of the long arm of chromosome 5 (5q-).
Lishner M; Amato D; Chalvardjian P; Baker MA; Fernandes B; Pantalony D; Dube ID
Clin Lab Haematol; 1991; 13(1):87-92. PubMed ID: 2060266
[TBL] [Abstract][Full Text] [Related]
12. 5q- and disordered haematopoiesis.
Bunn HF
Clin Haematol; 1986 Nov; 15(4):1023-35. PubMed ID: 3552346
[No Abstract] [Full Text] [Related]
13. 5q- syndrome terminating in acute myeloid leukemia. Karyotype evolution and immunologic characterization of blast cells.
Donti E; Tabilio A; Donti GV; Mecucci C; Carotti A; Grignani F; Martelli MF
Cancer Genet Cytogenet; 1988 Jun; 32(2):205-9. PubMed ID: 3163260
[TBL] [Abstract][Full Text] [Related]
14. Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients.
Pedersen B; Jensen IM
Leukemia; 1991 Jul; 5(7):566-73. PubMed ID: 2072742
[TBL] [Abstract][Full Text] [Related]
15. Hematologic and clinical features of patients with chromosome 5 monosomy or deletion (5q).
Brusamolino E; Orlandi E; Morra E; Bernasconi P; Pagnucco G; Colombo A; Lazzarino M; Bernasconi C
Med Pediatr Oncol; 1988; 16(2):88-94. PubMed ID: 3352540
[TBL] [Abstract][Full Text] [Related]
16. Clonal evolution in a transforming 5q- syndrome.
Kandioler D; Krieger O; Nowotny H; Lutz D
Leukemia; 1994 Apr; 8(4):711-2. PubMed ID: 8152269
[No Abstract] [Full Text] [Related]
17. Association of the Philadelphia chromosome and 5q- in secondary blood disorder.
Dastugue N; Demur C; Pris F; Bugat R; Attal M; Bourrouillou G; Colombies P
Cancer Genet Cytogenet; 1988 Feb; 30(2):253-9. PubMed ID: 3422579
[TBL] [Abstract][Full Text] [Related]
18. The role of lenalidomide in the management of myelodysplasia with del 5q.
Kelaidi C; Eclache V; Fenaux P
Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
[TBL] [Abstract][Full Text] [Related]
19. Evidence for 5q- occurring during the course of refractory anemia?
Swansbury GJ
Cancer Genet Cytogenet; 1987 Oct; 28(2):375. PubMed ID: 3621144
[No Abstract] [Full Text] [Related]
20. Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Killick S; Vyas P; Hellström-Lindberg E; Wainscoat JS; Boultwood J
Br J Haematol; 2011 Oct; 155(2):272-4. PubMed ID: 21492127
[No Abstract] [Full Text] [Related]
[Next] [New Search]
